Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

Boehringer Ingelheim

Status: Completed

Conditions: Parkinson Disease

Treatments: Drug: Sifrol®

Study type: Observational

Funder types: Industry

Identifiers

NCT02231255

248.517

Details and patient eligibility

About

Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for using Sifrol®, equivalent doses at the end of the switch and tolerability of Sifrol® in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions

Enrollment: 1,216 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Idiopathic Parkinson's disease who are planned to undergo a switch from another dopamine agonist to Sifrol®

Exclusion criteria

• Neurologists and psychiatrists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®

Trial design

1,216 participants in 1 patient group

Idiopathic Parkinson's disease patients

Treatment:

Drug: Sifrol®